UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

Related Keywords

North Carolina ,United States ,Chapel Hill ,Pardes Biosciences ,Mark Heise ,Tim Willson ,Williamr Kenan Jr ,Nathaniel Moorman ,Kevinm Guskiewicz ,Emily Henderson ,Gillings School Of Global Public Health ,Eshelman Institute For Innovation ,Chimerix Inc ,School Of Medicine ,Readdi Avidd Center ,Antiviral Drug Discovery Center ,Gillings School ,Antiviral Drug Development Initiative ,National Institute Of Allergy ,National Institutes Of Health ,Eshelman School Of Pharmacy ,Antiviral Program For Pandemics ,Janssen Pharmaceuticals ,National Institute ,Infectious Diseases ,National Institutes ,Global Public Health ,Ralph Baric ,Distinguished Professor ,Chapel Hill Chancellor Kevin ,Creativity Hubs ,Eshelman Institute ,Associate Professor ,Immunology Nathaniel Moorman ,Antiviral Drug ,Allergy ,Covid 19 ,Drug Discovery ,Drugs ,Mmunology ,Medicine ,Icrobiology ,Pandemic ,Mh ,Pharmacy ,Public Health ,Research ,Viral Disease ,